Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:52:46.097Z.
Calculation as of: 2026-10-06T18:52:46.097Z.
Quote observation: 2026-10-06T18:49:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4aebd5d53392a49c55eaf762d12be1f1a7ff494d091d9ceadcd34fda62bcd254
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$88.29M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $89.60M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.47M | 2.47 | 1.85 | 2.46 | 3.57 |
| CareCloud, Inc. (CCLD)vs › | $89.24M | 0.69 | 0.94 | 0.55 | 0.51 |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 2.94 | 2.48 | 2.09 | 2.48 |
| Rallybio Corporation (RLYB)vs › | $90.72M | 140.43 | 79.38 | 73.69 | 73.69 |
| Equillium, Inc. (EQ)vs › | $91.05M | N/A | 5.13 | 2.35 | 2.35 |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $88.29M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $91.78M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $86.77M | 14.01 | 5.23 | 5.24 | 18.61 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-06 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
